ArticleClinical drug investigation2025

The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2- Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered.

Asal Pilehvari et al.PubMed ↗Publisher ↗

No numbers read from the abstract.